Serplulimab plus chemo before surgery for limited stage small cell esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery can help people with limited-stage small cell carcinoma of the esophagus. It aims to see if this combination shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of esophageal cancer called small cell carcinoma, and it is in a limited stage (has not spread far).
- You are in generally good health (able to perform daily activities without major help).
- Your blood work shows adequate kidney, liver, and blood cell function.
- You have not had prior immunotherapy or certain other immune treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (serplulimab) and two chemotherapy drugs (nab-paclitaxel and cisplatin) given before surgery for esophageal cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improve outcomes for patients with stage IB to III esophageal squamous cell carcinoma.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Hear when a new Small-Cell Carcinoma of the Esophageal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.